Spironolactone Tablet, Film Coated
Product Images NDC 51655-153

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 51655-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 153 26 Rev A 04 23)

Label for spironolactone tablets USP, 100 mg, film-coated oral tablets. The package contains 90 tablets and is labeled for prescription use only. Storage instructions specify keeping at controlled room temperature (20°-25°C or 68°-77°F), out of reach of children, in the original container, and protected from light. The product is repackaged by Northwind Pharmaceuticals, Indianapolis, IN.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

Chemical structure of spironolactone showing its steroid core with a thioacetyl side chain and a lactone ring, consistent with its molecular composition as an active ingredient.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

A line chart comparing probability over time in months for spironolactone versus placebo groups. The chart shows higher probability for spironolactone (n=822) compared to placebo (n=841) over approximately 42 months, with a log-rank p-value less than 0.001 indicating statistical difference.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

A forest plot diagram showing hazard ratios (HR) and 95% confidence intervals (CI) for various patient subgroups treated with spironolactone versus placebo. The subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot visually compares the effectiveness of spironolactone across these categories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.